Chronic caffeine alters the density of adenosine, adrenergic, cholinergic, GABA, and serotonin receptors and calcium channels in mouse brain.
1. Chronic ingestion of caffeine by male NIH strain mice alters the density of a variety of central receptors. 2. The density of cortical A1 adenosine receptors is increased by 20%, while the density of striatal A2A adenosine receptors is unaltered. 3. The densities of cortical beta 1 and cerebellar beta 2 adrenergic receptors are reduced by ca. 25%, while the densities of cortical alpha 1 and alpha 2 adrenergic receptors are not significantly altered. Densities of striatal D1 and D2 dopaminergic receptors are unaltered. The densities of cortical 5 HT1 and 5 HT2 serotonergic receptors are increased by 26-30%. Densities of cortical muscarinic and nicotinic receptors are increased by 40-50%. The density of cortical benzodiazepine-binding sites associated with GABAA receptors is increased by 65%, and the affinity appears slightly decreased. The density of cortical MK-801 sites associated with NMDA-glutaminergic receptors appear unaltered. 4. The density of cortical nitrendipine-binding sites associated with calcium channels is increased by 18%. 5. The results indicate that chronic ingestion of caffeine equivalent to about 100 mg/kg/day in mice causes a wide range of biochemical alterations in the central nervous system.
Shi
D
D
Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892.
Nikodijević
O
O
Jacobson
K A
KA
Daly
J W
JW
D000818:Animals; D001923:Brain Chemistry / Q000187:drug effects*; D002110:Caffeine / Q000008:administration & dosage / Q000494:pharmacology*; D015220:Calcium Channels / Q000187:drug effects*; D002531:Cerebellum / Q000737:chemistry / Q000187:drug effects; D002540:Cerebral Cortex / Q000737:chemistry / Q000187:drug effects; D003342:Corpus Striatum / Q000737:chemistry / Q000187:drug effects; D008297:Male; D051379:Mice; D011941:Receptors, Adrenergic / Q000145:classification / Q000187:drug effects; D011950:Receptors, Cholinergic / Q000145:classification / Q000187:drug effects; D011954:Receptors, Dopamine / Q000032:analysis; D018079:Receptors, GABA / Q000145:classification / Q000187:drug effects; D017470:Receptors, Glutamate / Q000032:analysis; D017981:Receptors, Neurotransmitter / Q000187:drug effects*; D018047:Receptors, Purinergic P1 / Q000145:classification / Q000187:drug effects; D011985:Receptors, Serotonin / Q000145:classification / Q000187:drug effects
D015220:Calcium Channels; D011941:Receptors, Adrenergic; D011950:Receptors, Cholinergic; D011954:Receptors, Dopamine; D018079:Receptors, GABA; D017470:Receptors, Glutamate; D017981:Receptors, Neurotransmitter; D018047:Receptors, Purinergic P1; D011985:Receptors, Serotonin; D002110:Caffeine